Single-agent mTOR inhibitors have some efficacy in RCC, and co-targeting additional PI3K pathway members along with mTOR might be a valuable strategy for overcoming the escape mechanisms that can limit activity of mTOR inhibitors. This evidence concerns the gene MTOR and renal cell carcinoma.